Medical device company Zimmer Biomet (NYSE: ZBH) reported Q3 2026 results topping the market’s revenue expectations, with sales up 3.1% year on year to $2.06 billion. Its non-GAAP profit of $1.90 per share was 1% above analysts’ consensus estimates.

Is now the time to buy ZBH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Zimmer Biomet’s latest quarter drew a positive market response, reflecting broad-based growth across most business lines despite continued pressure in the knee franchise. Management attributed the company’s performance to upper single-digit or double-digit gains in hips, S.E.T. (sports medicine, extremities, and trauma), and technology and data, with CEO Ivan Tornos highlighting the success of new product cycles and commercial execution improvements. Notably, expansion in robotics and the integration of Paragon 28 drove significant momentum, helping to counter expected declines in knees and ongoing headwinds in China.

Looking ahead, management’s updated outlook is anchored by expectations of stable market dynamics and further gains from portfolio diversification and innovation. Tornos cited the anticipated FDA submission and, pending regulatory clearance, potential launch of the fully autonomous Monogram robotic platform in the first half of 2027, as well as the completion of the U.S. sales force transformation, as pivotal drivers for future growth. While acknowledging risks tied to ongoing knee franchise challenges and China-related disruptions, the company expects operational improvements and targeted investments to expand margins over time. As Tornos emphasized, "We truly believe that this technology will represent a dramatic leap forward for the future of orthopedic care."

Key insights from management’s remarks

Management pointed to portfolio diversification, strong new product uptake, and operational changes as the primary drivers behind the quarter’s performance and the raised full-year outlook.

• Portfolio diversification gains: The shift from a primarily joint reconstruction business to a broader offering in S.E.T., technology, and higher-growth orthopedics segments underpinned consistent growth outside of the knee franchise.
• Hip and S.E.T. growth: Strong performance in hips (driven by Cyclic Strength and HAMMR) and S.E.T. (notably Paragon 28 and upper extremities) validated the company’s innovation focus and was cited as sustainable by management.
• Technology and robotics expansion: Double-digit growth in technology and data was primarily powered by adoption of the ROSA with OptimiZe and TMINI robotic systems, as well as the OrthoGrid platform, which saw its strongest quarter to date with a significant portion of sales from recurring revenue.
• Knee franchise headwinds: U.S. knee sales declined due to sales force transition and competitive pressures, but management remains confident that strategic investments, new product launches, and improved execution will eventually restore growth.
• Operational improvements and cost focus: Ongoing manufacturing consolidation, thoughtful implementation of artificial intelligence capabilities with third-party experts, and reduced sales rep turnover are expected to improve long-term margin potential, even as near-term operating expenses remain elevated.

Drivers of future performance

Zimmer Biomet’s forward guidance is grounded in portfolio innovation, execution on U.S. sales transformation, and operational efficiency, while managing knee business recovery and international headwinds.

• Monogram robotic launch and adoption: The anticipated FDA submission and, contingent on regulatory clearance, potential launch of the fully autonomous Monogram platform in the first half of 2027 is expected to expand the company’s reach among surgeons not currently using robotics, supporting higher growth in technology-enabled procedures and driving share gains in knee and other joints.
• Sales force transformation and execution: Completion of the U.S. sales force specialization to a fully dedicated and specialized sales force is expected to reduce commercial execution risks and enable stronger growth in underpenetrated franchises, though management notes the final phase carries the most implementation risk and will require continued investment.
• Margin improvement initiatives: Manufacturing network optimization, thoughtfully implemented AI capabilities, and global capability centers are planned to drive operating leverage and reduce the company’s OPEX-to-sales ratio over time, though short-term expenses will remain elevated as investments in sales and innovation continue.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) progress on the FDA submission and the timing and outcome of regulatory review for the Monogram robotic system, (2) completion and impact of the U.S. sales force transformation on knee and overall franchise growth, and (3) execution of operational improvement initiatives, including manufacturing consolidation and the implementation of AI capabilities. Additional drivers include the continued integration and performance of Paragon 28 and new product rollouts within S.E.T. and technology segments.

Zimmer Biomet currently trades at $110.03, up from $97.09 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.